- Home
- VYNE
as 07-26-2024 4:00pm EST
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 38.2M | IPO Year: | 2018 |
| Target Price: | $5.75 | AVG Volume (30 days): | 47.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.57 - $6.79 | Next Earning Date: | 08-12-2024 |
| Revenue: | $423,000 | Revenue Growth: | 6.28% |
| Revenue Growth (this year): | 8.25% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of VYNE Therapeutics Inc. (VYNE)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LEPORE PATRICK G | VYNE | Director | Nov 15 '23 | Buy | $3.91 | 13,000 | $50,778.00 | 36,472 | SEC Form 4 |
Latest VYNE Therapeutics Inc. News
VYNE Breaking Stock News: Dive into VYNE Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor
Simply Wall St.
15 days ago
One VYNE Therapeutics Insider Raised Stake By 55% In Previous Year
GlobeNewswire
17 days ago
VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development
GlobeNewswire
a month ago
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
GlobeNewswire
a month ago
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
CNW Group
2 months ago
Lotto 6/49 - $64 million up for grabs in the next draw!
Simply Wall St.
2 months ago
Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
AFP
2 months ago
Seoul says it will resume loudspeaker propaganda against North
Compare VYNE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VYNE VYNE Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.